Product Description
Methamphetamine is a powerful, highly addictive stimulant that affects the central nervous system. Methamphetamine increases the amount of the natural chemical dopamine in the brain. (Sourced from: https://nida.nih.gov/publications/drugfacts/methamphetamine)
Mechanisms of Action: ADR Agonist,DR Agonist,SRI Inhibitor,DRI Inhibitor,NaR Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Belgium | Canada | Chile | Colombia | Dominican Republic | Egypt | Hong Kong | India | Korea | New Zealand | Peru | Philippines | Taiwan | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Affect Therapeutics
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Methamphetamine Dependence
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CS-1103-02 | P2 |
Not yet recruiting |
Methamphetamine Dependence |
2025-09-01 |